CD19-CAR-T cell therapy (China Immunotech/Avalon Globocare)

N/A

Report date: 2026/03/31 20:00:21

Base Information

Drug NameCD19-CAR-T cell therapy (China Immunotech/Avalon Globocare)
Drug Alias NameAVA-001 (Avalon GloboCare)AVA-001
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesChina Immunotech Co LtdAvalon Globocare Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAvalon Globocare CorpChina Immunotech Co Ltd
Active IndicationsN/A
Inactive IndicationsLymphoma, B-CellLeukemia, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A